Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 10 versus PROMAPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 10 versus PROMAPAR.
ETRAFON 2-10 vs PROMAPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON 2-10 is a combination of the phenothiazine antipsychotic perphenazine and the tricyclic antidepressant amitriptyline. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic neurotransmission in the mesolimbic pathway, while amitriptyline inhibits serotonin and norepinephrine reuptake, enhancing monoaminergic signaling.
PROMAPAR is a brand name for tramadol, a centrally acting analgesic that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, modulating pain perception.
1-2 tablets (perphenazine 2 mg / amitriptyline 10 mg) orally 3-4 times daily; max 8 tablets/day.
5 mg orally twice daily, titrated up to maximum 60 mg/day in divided doses.
None Documented
None Documented
The terminal elimination half-life is approximately 9-10 hours for perphenazine and 18-24 hours for amitriptyline; amitriptyline's active metabolite nortriptyline has a half-life of 18-44 hours, necessitating once-daily dosing for maintenance.
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-15 hours in moderate-to-severe renal impairment.
Elimination is primarily renal (50-70% as metabolites, <5% unchanged) and biliary/fecal (30-50% as metabolites).
Primarily renal (70-80% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for approximately 20%.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic